October 8, 2024 -- InvestorsHub NewsWire --
Bounce Mobile Systems Inc. (BNCM)
and DELEX Healthcare Group Inc. (DELEX) have successfully completed
their merger and unveiled their post-merger and management
plans.
DELEX, a Delaware-registered company, serves as
the holding company for DLX Holdings, Inc. (DLX). DLX, based in the
Philippines, holds a 60% controlling interest in DELEX Pharma
International, Inc., one of the fastest players in the
pharmaceutical and medical device industries in the
country.
1. Management
Transfer
The transition of BNCM management to DELEX will
commence in January 2025. BNCM's team will continue to provide
advisory support to the new management in compliance and
operational matters during this transition period, ensuring a
smooth handover of responsibilities.
2. DELEX Management
Team
DELEX Pharma, diversifying in fifteen (15)
years of operation, is an ISO 9001:2015-certified company, ranked
as the 3rd largest national company in hospital channels according
to IQVIA. DELEX Pharma's Board and Executive Committee bring over
more than three (3) decades of experience or leadership in the
healthcare sector, reinforcing the company's continuous
growth.
3. BNCM Q3 FS
Report
BNCM's Q3 Financial Statement (FS) will reflect
DELEX's revenue, assets, and liabilities, providing stakeholders
with transparency into the merger's financial impacts.
4. Asset & Revenue
Transfer to BNCM
The transfer of DELEX's assets and revenues to
BNCM will be completed by November 15, 2024, alongside the transfer
of shares representing 59.25% of the shareholding to DHG
management.
5. DELEX Audited
Financials
DELEX's financials are audited by SGV &
Co., a member of Ernst & Young International. SGV is the
leading and largest professional services firm in the Philippines
that provides assurance, consulting, tax, strategy and transactions
services, The audited financials for 2023 will be issued in
December, with the 2024 audit to follow in April 2025.
6. Announcement of Name
Change and Ticker Symbol
A formal application to rename BNCM to DELEX
and update the ticker symbol is scheduled for Q4 2024, aligning
with the new direction of the merged company.
7. DELEX Expansion
Plans
DELEX is positioned for aggressive growth, with
several key initiatives:
A. Expand Distribution
Channels
DELEX is expanding its distribution channels by
forging strategic partnerships with healthcare providers to create
integrated healthcare solutions. DELEX currently supplies to
nearly 700 hospitals nationwide and has established
a presence in over 900 Mercury Drug branches, serving more than 160
additional drug chains and reaching nearly 400 dispensing medical
doctors and clinics, thereby leveraging market development. Looking
ahead, DELEX aims to collaborate with more specialized care
facilities to strengthen its value proposition and support the
broader healthcare ecosystem in the Philippines.
B. Expand Product
Development
DELEX currently holds over
30 Hospital Products
approved by the Philippine FDA, more than 20
medical device products, and over 4 women's health brands, all
contributing to the company's revenue growth. In the first quarter
of the year, DELEX launched an impressive array of 11 new
pharmaceutical products and secured distributorship agreements with
4 multinational medical device companies, positioning itself for
significant growth across multiple therapeutic and diagnostic
areas.
C. Expand Medical
Device Business
To capitalize on the rapidly expanding medical
device market in the Philippines, which is projected to grow at an
annual rate of 8.14% (CAGR 2024-2029) and reach a market volume of
US$1.39 billion by 2029, DELEX amplified alliances with leading
international medical device companies such as Amsino, Masimo, and
Verathon in the U.S., as well as SternMed GmbH in Germany. These
collaborations are anticipated to significantly enhance DELEX's
growth in the medical device business unit.
D. Expand Retail
Pharmacy Business
A recent study highlights that the pharmacy
market is projected to grow at an annual rate of 3.77% (CAGR
2024-2029), resulting in a market volume of approximately US$7.75
billion by 2029. In response to this opportunity, DELEX established
its first branch in Barangay Sauyo, Quezon City in October 2021, to
serve the densely populated community and surrounding areas during
the pandemic. Since then, the company has expanded to two
additional branches, totaling three drugstores, with two
strategically located near hospitals to facilitate high-volume
purchases. DELEX will continue to develop its drugstore business by
positioning new locations near hospitals that accommodate
prescription spills and by exploiting untapped areas in the country
to generate positive sales growth for the company.
E. Expand Market Reach
Through DELEX ICU Forum
DELEX has transcended its on-ground ICU Forum
to online—a free webinar series for healthcare providers during the
pandemic—that has since attracted a global audience of nearly
200,000 healthcare professionals. This platform facilitates
discussions on best practices, advancements in critical care
techniques, innovations in treatment protocols, and networking
among healthcare communities. Additionally, this initiative has
fostered partnerships with over 50 hospital departments and medical
societies in the Philippines, significantly enhancing the
company's visibility among its target audience.
8. Post Merger Share
Structure
DELEX Group will hold a majority stake in BNCM,
accounting for 59.25%, while BNCM will hold 15.75%, with other
shareholders retaining the remaining shares. This post-merger share
structure will be finalized and announced in the Q4
report.
9. Capital Raise and
Regulation A Application
DELEX will apply for Regulation A with the SEC
to support its expansion plans as detailed in this article.
About Bounce Mobile
Systems, Inc. (OTC:
BNCM)
BNCM is an Asset Management Company that
secures its assets by investing in companies with strong growth
potentials, robust revenues, significant profits, proven track
records, and promising business models with highly experienced
management teams that will exceptionally qualify for quotation and
listing on the OTC or NASDAQ markets within the next 2 to 3 years.
The growth of these companies will directly provide more employment
opportunities to the communities, improve the country's economy,
and bring greater social change.
For more information,
visit:
https://www.bncm.net/
About Delex Healthcare
Group, Inc. (DELEX)
DELEX is a Delaware-registered company, and the
holding company of DLX Holdings, Inc. (DLX). DLX is a
Philippine-based parent company that holds a 60% controlling
interest in DELEX Pharma International, Inc. an ISO 9001-2015
Certified company, which also holds a controlling interest in JMN
Brother's Pharma Limited, Inc. DLX and its subsidiaries are
involved in the development and distribution of pharmaceutical and
healthcare products in the Philippines.
For more information,
visit:
https://delexhealth.com